CLINICAL STUDY
Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin t genes in hypertrophic cardiomyopathy
A comprehensive outpatient perspective
Michael J. Ackerman, MD, PhD*  ,*,
Sara L. VanDriest, BA,
Steve R. Ommen, MD, FACC*,
Melissa L. Will, BS*,
Rick A. Nishimura, MD, FACC*,
A. Jamil Tajik, MD, FACC* and
Bernard J. Gersh, MB, ChB, DPhil, FACC*
* Department of Internal Medicine/Division of Cardiovascular DiseasesRochester, Minnesota, USA
Pediatric and Adolescent Medicine/Division of Pediatric CardiologyRochester, Minnesota, USA
Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
Manuscript received June 14, 2001;
revised manuscript received February 20, 2002,
accepted April 1, 2002.
* Reprint requests and correspondence: Dr. Michael J. Ackerman, Pediatric Cardiology E9, Mayo Clinic, 200 First Street, Rochester, Minnesota 55905 USA.
ackerman.michael{at}mayo.edu
OBJECTIVES: The goal of this study was to determine the prevalence of "malignant" mutations in hypertrophic cardiomyopathy (HCM).
BACKGROUND: Previous genotype-phenotype studies have implicated four mutations (R403Q, R453C, G716R and R719W) as highly malignant defects in the beta-myosin heavy chain (MYH7). In the cardiac troponin T gene (TNNT2), a specific mutation (R92W) has been associated with high risk of sudden death. Routine clinical screening for these malignant mutations has been suggested to identify high-risk individuals.
METHODS: We screened 293 unrelated individuals with HCM seen at the Mayo Clinic in Rochester, Minnesota, between April 1997 and October 2000. Deoxyribonucleic acid (DNA) was obtained after informed consent; amplification of MYH7 exons 13 (R403Q), 14 (R453C) and 19 (G716R and R719W), and TNNT2 exon 9 (R92W) was performed by polymerase chain reaction. The mutations were detected using denaturing high-performance liquid chromatography and automated DNA sequencing.
RESULTS: The mean age at diagnosis was 42 years with 53 patients diagnosed before age 25. The mean maximal left ventricular wall thickness was 21 mm. Nearly one-third of cases were familial and one-fourth had a family history of sudden cardiac death. Only 3 of the 293 patients possessed one of the five "malignant" mutations, and all 3 patients were <25 years of age at presentation (p < 0.006).
CONCLUSIONS: This finding underscores the profound genetic heterogeneity in HCM. Only 1% of unrelated individuals seen at a tertiary referral center for HCM possessed one of the five "malignant" mutations that were examined. Routine clinical testing for these specific mutations is of low yield.
|
Abbreviations and Acronyms
| | DHPLC | | denaturing high-performance liquid chromatography | | DNA | | deoxyribonucleic acid | | HCM | | hypertrophic cardiomyopathy | | ICD | | implanted cardioverter defibrillator | | LVOTO | | left ventricular outflow tract obstruction | | LVWT | | left ventricular wall thickness | | MYH7 | | cardiac beta-myosin heavy chain | | PCR | | polymerase chain reaction | | SCD | | sudden cardiac death | | TNNT2 | | troponin T |
|
This article has been cited by other articles:
|
|
|
|
 
K. J. Hogan, J. K. Burmester, M. D. Caldwell, Q. H. Hogan, D. B. Coursin, D. N. Green, R. M.R. Selzer, T. P. Broderick, D. A. Rusy, M. Poroli, et al.
Perioperative Genomic Profiles Using Structure-Specific Oligonucleotide Probes
Clin. Med. Res.,
September 1, 2009;
7(3):
69 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Bos, J. A. Towbin, and M. J. Ackerman
Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy.
J. Am. Coll. Cardiol.,
July 14, 2009;
54(3):
201 - 211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, W. C. Roberts, M. Arad, T. S. Haas, P. Spirito, G. B. Wright, A. K. Almquist, J. M. Baffa, J. P. Saul, C. Y. Ho, et al.
Clinical Outcome and Phenotypic Expression in LAMP2 Cardiomyopathy
JAMA,
March 25, 2009;
301(12):
1253 - 1259.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G S Soor, A Luk, E Ahn, J R Abraham, A Woo, A Ralph-Edwards, and J Butany
Hypertrophic cardiomyopathy: current understanding and treatment objectives
J. Clin. Pathol.,
March 1, 2009;
62(3):
226 - 235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, C. E. Seidman, M. J. Ackerman, J. A. Towbin, M. S. Maron, S. R. Ommen, R. A. Nishimura, and B. J. Gersh
How should hypertrophic cardiomyopathy be classified?: What's in a Name? Dilemmas in Nomenclature Characterizing Hypertrophic Cardiomyopathy and Left Ventricular Hypertrophy
Circ Cardiovasc Genet,
February 1, 2009;
2(1):
81 - 86.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Elliott and W. J. McKenna
How should hypertrophic cardiomyopathy be classified?: Molecular Diagnosis for Hypertrophic Cardiomyopathy: Not Ready for Prime Time
Circ Cardiovasc Genet,
February 1, 2009;
2(1):
87 - 89.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Michels, O. I.I. Soliman, M. J. Kofflard, Y. M. Hoedemaekers, D. Dooijes, D. Majoor-Krakauer, and F. J. ten Cate
Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.
J. Am. Coll. Cardiol. Img.,
January 1, 2009;
2(1):
58 - 64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Olivotto, F. Girolami, M. J. Ackerman, S. Nistri, J. M. Bos, E. Zachara, S. R. Ommen, J. L. Theis, R. A. Vaubel, F. Re, et al.
Myofilament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic Cardiomyopathy
Mayo Clin. Proc.,
June 1, 2008;
83(6):
630 - 638.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Ostman-Smith, G. Wettrell, B. Keeton, D. Holmgren, U. Ergander, S. Gould, C. Bowker, and M. Verdicchio
Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy
Eur. Heart J.,
May 1, 2008;
29(9):
1160 - 1167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Nishimura and S. R. Ommen
Hypertrophic Cardiomyopathy: The Search for Obstruction
Circulation,
November 21, 2006;
114(21):
2200 - 2202.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Cesario and G. W. Dec
Implantable Cardioverter- Defibrillator Therapy in Clinical Practice
J. Am. Coll. Cardiol.,
April 18, 2006;
47(8):
1507 - 1517.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Binder, S. R. Ommen, B. J. Gersh, S. L. Van Driest, A. J. Tajik, R. A. Nishimura, and M. J. Ackerman
Echocardiography-Guided Genetic Testing in Hypertrophic Cardiomyopathy: Septal Morphological Features Predict the Presence of Myofilament Mutations
Mayo Clin. Proc.,
April 1, 2006;
81(4):
459 - 467.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Ladich, R. Virmani, and A. Burke
Sudden Cardiac Death not Related to Coronary Atherosclerosis
Toxicol Pathol,
January 1, 2006;
34(1):
52 - 57.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Perkins, S. L. Van Driest, E. G. Ellsworth, M. L. Will, B. J. Gersh, S. R. Ommen, and M. J. Ackerman
Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy
Eur. Heart J.,
November 2, 2005;
26(22):
2457 - 2462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Ackerman, S. L. Van Driest, and M. Bos
Are Longitudinal, Natural History Studies the Next Step in Genotype-Phenotype Translational Genomics in Hypertrophic Cardiomyopathy?
J. Am. Coll. Cardiol.,
November 1, 2005;
46(9):
1744 - 1746.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Van Driest, S. R. Ommen, A. J. Tajik, B. J. Gersh, and M. J. Ackerman
Yield of Genetic Testing in Hypertrophic Cardiomyopathy
Mayo Clin. Proc.,
June 1, 2005;
80(6):
739 - 744.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. L. Van Driest, S. R. Ommen, A. J. Tajik, B. J. Gersh, and M. J. Ackerman
Sarcomeric Genotyping in Hypertrophic Cardiomyopathy
Mayo Clin. Proc.,
April 1, 2005;
80(4):
463 - 469.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Mogensen, R. T. Murphy, T. Kubo, A. Bahl, J. C. Moon, I. C. Klausen, P. M. Elliott, and W. J. McKenna
Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy
J. Am. Coll. Cardiol.,
December 21, 2004;
44(12):
2315 - 2325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, J.G. Seidman, and C. E. Seidman
Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy
J. Am. Coll. Cardiol.,
December 7, 2004;
44(11):
2125 - 2132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Van Driest, M. A. Jaeger, S. R. Ommen, M. L. Will, B. J. Gersh, A. J. Tajik, and M. J. Ackerman
Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy
J. Am. Coll. Cardiol.,
August 4, 2004;
44(3):
602 - 610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, B. R. Chaitman, M. J. Ackerman, A. Bayes de Luna, D. Corrado, J. E. Crosson, B. J. Deal, D. J. Driscoll, N.A. M. Estes III, C. G. S. Araujo, et al.
Recommendations for Physical Activity and Recreational Sports Participation for Young Patients With Genetic Cardiovascular Diseases
Circulation,
June 8, 2004;
109(22):
2807 - 2816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P Frenneaux
Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy
Heart,
May 1, 2004;
90(5):
570 - 575.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S L Van Driest, B J Maron, and M J Ackerman
From malignant mutations to malignant domains: the continuing search for prognostic significance in the mutant genes causing hypertrophic cardiomyopathy
Heart,
January 1, 2004;
90(1):
7 - 8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Ackerman, D. J. Tester, G. S. Jones, M. L. Will, C. R. Burrow, and M. E. Curran
Ethnic Differences in Cardiac Potassium Channel Variants: Implications for Genetic Susceptibility to Sudden Cardiac Death and Genetic Testing for Congenital Long QT Syndrome
Mayo Clin. Proc.,
December 1, 2003;
78(12):
1479 - 1487.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
J. Am. Coll. Cardiol.,
November 5, 2003;
42(9):
1687 - 1713.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al.
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines
Eur. Heart J.,
November 1, 2003;
24(21):
1965 - 1991.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Woo, H Rakowski, J C Liew, M-S Zhao, C-C Liew, T G Parker, M Zeller, E D Wigle, and M J Sole
Mutations of the {beta} myosin heavy chain gene in hypertrophic cardiomyopathy: critical functional sites determine prognosis
Heart,
October 1, 2003;
89(10):
1179 - 1185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B J Maron
Contemporary considerations for risk stratification, sudden death and prevention in hypertrophic cardiomyopathy
Heart,
September 1, 2003;
89(9):
977 - 978.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Garcia-Castro, J. R. Reguero, A. Batalla, B. Diaz-Molina, P. Gonzalez, V. Alvarez, A. Cortina, G. I. Cubero, and E. Coto
Hypertrophic Cardiomyopathy: Low Frequency of Mutations in the {beta}-Myosin Heavy Chain (MYH7) and Cardiac Troponin T (TNNT2) Genes among Spanish Patients
Clin. Chem.,
August 1, 2003;
49(8):
1279 - 1285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Van Driest, E. G. Ellsworth, S. R. Ommen, A. J. Tajik, B. J. Gersh, and M. J. Ackerman
Prevalence and Spectrum of Thin Filament Mutations in an Outpatient Referral Population With Hypertrophic Cardiomyopathy * Note Added in Proof
Circulation,
July 29, 2003;
108(4):
445 - 451.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Hengstenberg, J Erdmann, and P Charron
Outcome of clinical versus genetic family screening in hypertrophic cardiomyopathy with focus on cardiac beta-myosin gene mutations: Prediction of clinical status--is molecular genetics a new tool for the management of hypertrophic cardiomyopathy in clinical practice?
Cardiovasc Res,
February 1, 2003;
57(2):
298 - 301.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Van Driest, M. J. Ackerman, S. R. Ommen, R. Shakur, M. L. Will, R. A. Nishimura, A. J. Tajik, and B. J. Gersh
Prevalence and Severity of "Benign" Mutations in the {beta}-Myosin Heavy Chain, Cardiac Troponin T, and {alpha}-Tropomyosin Genes in Hypertrophic Cardiomyopathy
Circulation,
December 10, 2002;
106(24):
3085 - 3090.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. McKenna, J. Mogensen, and P. M. Elliott
Role of genotyping in risk factor assessment for sudden death in hypertrophic cardiomyopathy
J. Am. Coll. Cardiol.,
June 19, 2002;
39(12):
2049 - 2051.
[Full Text]
[PDF]
|
|
|
|
